MammaPrint^® & BluePrint^® are now available for patients in Canada

MammaPrint^®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint^®, the 80-gene molecular subtyping assay, evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint and BluePrint provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

Patient Support Program

We believe MammaPrint will be reimbursed in the same manner as other Gene Expression Profiling Tests (GEPT) through the out of country process based on the guidance from the Ontario Health Technology Advisory Committee published on March 2020. These recommendations are currently in final review by the Ministry. (Read more here).  

Please contact Agendia directly to find out if you qualify for our Financial Assistance Programs or to answer any question with regards to MammaPrint or BluePrint, whether the patient is lymph-node negative,  lymph-node positive, Clinical High Risk or Clinical Low Risk.

The clinical indications for MammaPrint are listed below:

• Early Stage Breast Cancer (Clin-Low or Clin-High)
• Tumor < 5 cm in size
• Estrogen receptor positive (ER+)
• Human epidermal growth factor receptor 2 negative (HER2-)
• Lymph-node negative or micrometastasis and Lymph-node Positive N1 (1-3 +LN)